CA3092750A1 - Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer - Google Patents
Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer Download PDFInfo
- Publication number
- CA3092750A1 CA3092750A1 CA3092750A CA3092750A CA3092750A1 CA 3092750 A1 CA3092750 A1 CA 3092750A1 CA 3092750 A CA3092750 A CA 3092750A CA 3092750 A CA3092750 A CA 3092750A CA 3092750 A1 CA3092750 A1 CA 3092750A1
- Authority
- CA
- Canada
- Prior art keywords
- buprenorphine
- therapeutic system
- transdermal therapeutic
- silicone
- containing layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161418 | 2018-03-13 | ||
| EP18161418.1 | 2018-03-13 | ||
| PCT/EP2019/056010 WO2019175096A1 (en) | 2018-03-13 | 2019-03-11 | Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092750A1 true CA3092750A1 (en) | 2019-09-19 |
Family
ID=61628178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092750A Pending CA3092750A1 (en) | 2018-03-13 | 2019-03-11 | Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210000755A1 (https=) |
| EP (1) | EP3764995A1 (https=) |
| JP (1) | JP2021517569A (https=) |
| CN (1) | CN111787913A (https=) |
| BR (1) | BR112020017484A2 (https=) |
| CA (1) | CA3092750A1 (https=) |
| WO (1) | WO2019175096A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4395749B1 (en) * | 2021-08-30 | 2025-11-19 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2024406B1 (en) | 2006-06-06 | 2012-08-01 | Dow Corning Corporation | A silicone acrylate hybrid composition |
| BRPI1014886B1 (pt) | 2009-04-24 | 2020-02-11 | Henkel IP & Holding GmbH | Polímeros acrílicos de silicone híbridos, seus métodos de preparação, adesivos e soluções de uma composição adesiva sensível à pressão compreendendo os mesmos. |
| CN103200944B (zh) * | 2010-11-17 | 2016-05-04 | 赫克萨尔股份公司 | 包含丁丙诺啡的经皮治疗系统 |
| JP2013139554A (ja) | 2011-11-29 | 2013-07-18 | Dow Corning Corp | シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法 |
| AU2013205080B2 (en) * | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
| WO2014195352A1 (en) * | 2013-06-04 | 2014-12-11 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
| US10316228B2 (en) | 2015-02-09 | 2019-06-11 | Dow Silicones Corporation | Multi-phase silicone acrylic hybrid visco-elastic compositions and methods of making same |
| EP3349737A4 (en) * | 2015-09-14 | 2019-05-15 | Amneal Pharmaceuticals LLC | SYSTEM FOR TRANSDERING |
| KR102381686B1 (ko) * | 2016-07-22 | 2022-04-01 | 에르테에스 로만 테라피-시스테메 아게 | 접착제 도메인의 제어 |
-
2019
- 2019-03-11 US US16/979,572 patent/US20210000755A1/en not_active Abandoned
- 2019-03-11 CA CA3092750A patent/CA3092750A1/en active Pending
- 2019-03-11 CN CN201980016022.8A patent/CN111787913A/zh active Pending
- 2019-03-11 JP JP2020548695A patent/JP2021517569A/ja not_active Abandoned
- 2019-03-11 BR BR112020017484-0A patent/BR112020017484A2/pt not_active Application Discontinuation
- 2019-03-11 WO PCT/EP2019/056010 patent/WO2019175096A1/en not_active Ceased
- 2019-03-11 EP EP19708860.2A patent/EP3764995A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021517569A (ja) | 2021-07-26 |
| WO2019175096A1 (en) | 2019-09-19 |
| BR112020017484A2 (pt) | 2020-12-22 |
| EP3764995A1 (en) | 2021-01-20 |
| US20210000755A1 (en) | 2021-01-07 |
| CN111787913A (zh) | 2020-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018348801B2 (en) | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | |
| CA3079697A1 (en) | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | |
| US11389421B2 (en) | Transdermal therapeutic system for the transdermal administration of rivastigmine | |
| US12121616B2 (en) | Transdermal therapeutic system for the transdermal administration of solifenacin | |
| US20210038532A1 (en) | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer | |
| US20210000756A1 (en) | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer | |
| CA3146233A1 (en) | Transdermal therapeutic system comprising an active agent-containing layer comprising a silicone-containing polymer and a skin contact layer comprising a silicone gel adhesive | |
| US20210052569A1 (en) | Transdermal therapeutic system containing nicotine and silicone acrylic hybrid polymer | |
| US20210000755A1 (en) | Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer | |
| US20210145760A1 (en) | Transdermal therapeutic system containing scopolamine and silicone acrylic hybrid polymer | |
| US20210008000A1 (en) | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer | |
| HK40043162A (en) | Transdermal therapeutic system for the transdermal administration of solifenacin |